@article{fbf52470a05747ca981d1fae05bcc825,
title = "Multiple sclerosis drugs: How much bang for the buck?",
author = "Olaf St{\"u}ve and Cutter, {Gary R.}",
note = "Funding Information: OS has received grant support from Teva Pharmaceuticals and Opexa Therapeutics, has served on data monitoring committees for Pfizer and Sanofi-Aventis without monetary compensation, has served on an advisory board for Sanofi Genzyme, and has advised TC Huron Life Sciences. OS is funded by a Merit grant from the US Department of Veterans Affairs. GC is a member if data and safety monitoring boards for Apotek, Biogen Idec, Cleveland Clinic (Vivus), Glaxo Smith Klein Pharmaceuticals, Gilead Pharmaceuticals, Modigenetech/Prolor, Merck/Ono Pharmaceuticals, Merck, Merck/Pfizer, Neuren, Sanofi-Aventis, Teva, Washington University, NHLBI (Protocol Review Committee), NINDS, and NICHD (OPRU oversight committee). GC is consulting or on advisory boards for the Consortium of MS Centers (grant), D3 (Drug Discovery and Development), Genzyme, Genentech, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Novartis, Opexa Therapeutics, Receptos, Roche, EMD Serono, Spiniflex Pharmaceuticals, Somahlution Pharmaceuticals, and Transparency Life Sciences. GC is President of Pythagoras, Inc, a private consulting company located in Birmingham, AL, USA. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",
year = "2015",
month = may,
day = "1",
doi = "10.1016/S1474-4422(15)00016-2",
language = "English (US)",
volume = "14",
pages = "460--461",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "5",
}